MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA

MLA

K. Sturgess, et al. “Modification of Escalated Beacopp with Dacarbazine Substitution Reduces Toxicity While Maintaining Efficacy for the Treatment of Advanced Stage Hodgkin Lymphoma.” Hematological Oncology, vol. 39, June 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d79f006a04cad37bad4f04e267e56ca6&authtype=sso&custid=ns315887.

APA

K. Sturgess, M. Furtado, G. Stafford, S. G. Jones, Tobias Menne, Andrew McMillan, Kaljit Bhuller, Thomas Creasey, Graham P. Collins, Deirdre O’Mahony, Anna Santarsieri, Sateesh K Nagumantry, George A Follows, Stephen Booth, John F. Rudge, Nicolas Martinez-Calle, Benjamin J Uttenthal, A. Sternberg, Pauline Brice, … Kirit M. Ardeshna. (2021). Modification of Escalated Beacopp with Dacarbazine Substitution Reduces Toxicity While Maintaining Efficacy for the Treatment of Advanced Stage Hodgkin Lymphoma. Hematological Oncology, 39.

Chicago

K. Sturgess, M. Furtado, G. Stafford, S. G. Jones, Tobias Menne, Andrew McMillan, Kaljit Bhuller, et al. 2021. “Modification of Escalated Beacopp with Dacarbazine Substitution Reduces Toxicity While Maintaining Efficacy for the Treatment of Advanced Stage Hodgkin Lymphoma.” Hematological Oncology 39 (June). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d79f006a04cad37bad4f04e267e56ca6&authtype=sso&custid=ns315887.